Mitotic kinesin inhibitors

1. The compound of the Formula III;

wherein:

R 1 is selected from: H, F and OH;

R 3 is selected from: H, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 2 -C 6 )alkenyl and (C 1 -C 6 )alkyl hydroxyl;

R 4 is selected from: H, oxo, OH, halo, CN, NH 2 , NO 2 , (C═O) a O b (C 1 -C 10 )alkyl, (C═O) a O b (C 2 -C 10 )alkenyl, (C═O) a O b (C 2 -C 10 )alkynyl, (C═O) a O b (C 3 -C 6 )cycloalkyl, (C═O) a O b (C 0 -C 6 )alkylene-aryl, (C═O) a O b (C 0 -C 6 )alkylene-heterocyclyl, (C═O) a O b (C 0 -C 6 )alkylene-N(R b ) 2 , C(O)H, (C 0 -C 6 )alkylene-CO 2 H, C(O)N(R b ) 2 , and S(O) 2 N(R b ) 2 ; said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, alkylene and heterocyclyl is optionally substituted with up to three substituents selected from R b ;

R 5 is H or CH 3 ;

R a is selected from: (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, aryl and heterocyclyl; said alkyl, cycloalkyl, aryl and heterocyclyl is optionally substituted with one or more substituents selected from OH,(C 1 - 6 )alkyl, (C 1 -C 6 )alkoxy, halogen, CO 2 H, CN, (O)C═O(C 1 -C 6 )alkyl, oxo and N(R c ) 2 ;

R b is independently selected from: H, oxo, OH, halogen, CO 2 H, CN, (O)C═O(C 1 -C 6 )alkyl, N(R c ) 2 , (C 1 -C 6 )alkyl, aryl, heterocyclyl, (C 3 -C 6 )cycloalkyl, (C═O)O(C 1 -C 6 )alkyl, C═O(C 1 -C 6 )alkyl and S(O) 2 R a ; said alkyl, cycloalkyl, aryl or heterocylyl is optionally substituted with one or more substituents selected from OH, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, halogen, CO 2 H, CN, (O)C═O(C 1 -C 6 )alkyl, oxo, N(R c ) 2 and optionally substituted heterocyclyl, wherein said heterocyclyl is optionally substituted with (C 1 -C 6 )alkyl, oxo or NH 2 ;

R c is independently selected from: H and (C 1 -C 6 )alkyl;

a is 0 or 1;

b is 0 or 1;

p is 1 or 2;

q is 0 or 1;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. The compound according to claim 1 of the Formula III;

wherein:

R 4 is selected from: H, oxo, OH, halo, CN, NH 2 , NO 2 , (C═O) a O b (C 1 -C 10 )alkyl, (C═O) a O b (C 2 -C 10 )alkenyl, (C═O) a O b (C 2 -C 10 )alkynyl, (C═O) a O b (C 3 -C 6 )cycloalkyl, (C═O) a O b (C 0 -C 6 )alkylene-aryl, (C═O) a O b (C 0 -C 6 )alkylene-heterocyclyl, (C═O) a O b (C 0 -C 6 )alkylene-N(R b ) 2 , C(O)H, (C 0 -C 6 )alkylene-CO 2 H, C(O)N(R b ) 2 , and S(O) 2 N(R b ) 2 ; said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, alkylene and heterocyclyl is optionally substituted with up to three substituents selected from R b ;

and all other substituents and variables are as defined in claim 1 ;

or a pharmaceutically acceptable salt or stereoisomer thereof.

3. The compound according to claim 1 of the Formula III;

wherein:

R 4 is selected from: H, oxo, OH, halo, CN, NH 2 , NO 2 , (C═O) a O b (C 1 -C 10 )alkyl, (C═O) a O b (C 2 -C 10 )alkenyl, (C═O) a O b (C 2 -C 10 )alkynyl, (C═O) a O b (C 0 -C 6 )alkylene-N(R b ) 2 , (C═O)—R b , C(O)H, (C 0 -C 6 )alkylene-CO 2 H, C(O)N(R b ) 2 , and S(O) 2 N(R b ) 2 ; said alkyl, alkenyl, alkynyl, and alkylene is optionally substituted with up to three substituents selected from R b ;

and all other substituents and variables are as defined in claim 1 ;

or a pharmaceutically acceptable salt or stereoisomer thereof.

4. A compound which is selected from:

3-[{3-chloro-4-fluorophenyl)(2-hydroxy-1-methylethyl)amino]methyl}phenol;

2-[benzyl(3-chloro-4-fluorophenyl)amino]propan-1-ol;

N-2-benzyl-N-2-(3-chloro-4-fluorophenyl)-N-1-[2(dimethylamino)ethyl]alaninamide;

N-2-benzyl-N-2-(3-chloro-4-fluorophenyl)alaninamide;

methyl N-benzyl-N-(3-chloro-4-fluorophenyl)alanylglycinate;

N-2-benzyl-N-2-(3-chloro-4-fluorophenyl)-N-1-(isoxazol-4-ylmethyl)alaninamide;

3-[benzyl(3-chloro-4-fluorophenyl)amino]-2-methylbutan-2-ol;

N-2-benzyl-N-2-(3-chloro-4-fluorophenyl)-N-1,N-1-dimethylpropane-1,2-diamine;

N-benzyl-3-chloro-4-fluoro-N-[1-methyl-2-(4-methylpiperazin-1-yl)ethyl]aniline;

2-[(3-chloro-4-fluorophenyl)(1-phenylethyl)amino]propan-1-ol;

N-2-(3-chloro-4-fluorophenyl)-N-2-(3-hydroxybenzyl)-N-1-(isoxazol)-4-ylmethyl)alaninamide;

N-2-(3-chloro-4-fluorophenyl)-N-2-(3-hydroxybenzyl)alaninamide;

N-2-(3-chloro-4-fluorophenyl)-N-1-[2-(dimethylamino)ethyl]-N-2-(3-hydroxybenzyl)alaninamide;

Methyl 2-[benzyl(3-chloro-4-fluorophenyl)amino]butanoate;

Methyl 2-[benzyl(3-chloro-4-fluorophenyl)amino]pent-4-enoate;

2-[benzyl(3-chloro-4-fluorophenyl)amino]pent-4-en-1-ol;

N-benzyl-N-(3-chloro-4-fluorophenyl)glycine;

2-[benzyl(3-chloro-4-fluorophenyl)amino]pentan-1-ol;

2-[benzyl(3-chloro-4-fluorophenyl)amino]butan-1-ol;

N-benzyl-3-chloro-N-[1-({3-[(dimethylamino)methyl]piperidin-1-yl}carbonyl)propyl]-4-fluoroaniline;

2-[benzyl(3-chloro-4-fluorophenyl)amino]-N-methyl-N-[2-(1-methyl-1H-pyrazol-4-yl)ethyl]butanamide;

2-[benzyl(3-chloro-4-fluorophenyl)amino]-3-methylbutan-1-ol;

2-[benzyl(3-chloro-4-fluorophenyl)amino]pentane-1,5-diol;

2-[benzyl(3-chloro-4-fluorophenyl)amino]-3-cyclopropylpropan-1-ol; and

N- 2 -benzyl-N- 2 -(3-chloro-4-fluorophenyl)-N 1 -[2-dimethylamino)ethyl]-2-methylalaninamide;

or a pharmaceutically acceptable salt or stereoisomer thereof.

5. The TFA salt of a compound according to claim 1 which is

3-[{3-chloro-4-fluorophenyl)(2-hydroxy-1-methylethyl)amino]methyl}phenol;

2-[benzyl(3-chloro-4-fluorophenyl)amino]propan-1-ol;

N-2-benzyl-N-2-(3-chloro-4-fluorophenyl)-N-1-[2(dimethylamino)ethyl]alaninamide;

N-2-benzyl-N-2-(3-chloro-4-fluorophenyl)alaninamide;

methyl N-benzyl-N-(3-chloro-4-fluorophenyl)alanylglycinate;

3-[benzyl(3-chloro-4-fluorophenyl)amino]-2-methylbutan-2-ol;

2-[(3-chloro-4-fluorophenyl)(1-phenylethyl)amino]propan-1-ol;

N-2-(3-chloro-4-fluorophenyl)-N-2-(3-hydroxybenzyl)-N-1-(isoxazol)-4-ylmethyl)alaninamide;

N-2-(3-chloro-4-fluorophenyl)-N-2-(3-hydroxybenzyl)alaninamide;

N-2-(3-chloro-4-fluorophenyl)-N-1-[2-(dimethylamino)ethyl]-N-2-(3-hydroxybenzyl)alaninamide;

N-benzyl-N-(3-chloro-4-fluorophenyl)glycine;

2-[benzyl(3-chloro-4-fluorophenyl)amino]pentan-1-ol;

2-[benzyl(3-chloro-4-fluorophenyl)amino]butan-1-ol;

N-benzyl-3-chloro-N-[1-({3-[(dimethylamino)methyl]piperidin-1-yl}carbonyl)propyl]-4-fluoroaniline;

2-[benzyl(3-chloro-4-fluorophenyl)amino]-N-methyl-N-[2-(1-methyl-1H-pyrazol-4-yl)ethyl]butanamide;

2-[benzyl(3-chloro-4-fluorophenyl)amino]pentane-1,5-diol; and

N- 2 -benzyl-N- 2 -(3-chloro-4-fluorophenyl)-N 1 -[2-dimethylamino)ethyl]-2-methylalaninamide;

or stereoisomer thereof.

6. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of claim 1 .